SCHEMBL4132544

SCHEMBL4132544

CC(=C1SC(Nc2ccc(CC(=O)O)cc2)=NC1=O)c1cc2ccccc2o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.42
PDE4D Q08499 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.41
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
TP53 P04637 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
PKM P14618 2/20 0.40
ATM Q13315 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
HPGD P15428 1/20 0.38
MAPK1 P28482 2/20 0.38
P2RY14 Q15391 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132534 1.00 PDE4B (0.42) PDE4BPDE4DPTGDR2NPC1RAB9A
SCHEMBL4134811 0.79 NR1H4 (0.50) PDE4BPDE4DGAA
SCHEMBL4134807 0.79 NR1H4 (0.50) PDE4BPDE4DGAA
SCHEMBL4132540 0.77 PDE4B (0.41) PDE4BPDE4DMEN1KMT2AMAPT
SCHEMBL4634520 0.74 NR1H4 (0.51) PDE4BPDE4DPTGDR2NPC1RAB9A
SCHEMBL4634512 0.74 NR1H4 (0.51) PDE4BPDE4DPTGDR2NPC1RAB9A
SCHEMBL4120866 0.74 PTGS1 (0.48) PDE4BPDE4DMEN1KMT2AMAPT
SCHEMBL4120873 0.74 PTGS1 (0.48) PDE4BPDE4DMEN1KMT2AMAPT
SCHEMBL4127967 0.73 CTDSP1 (0.42) PDE4BPDE4DTP53MEN1KMT2A
SCHEMBL4127965 0.73 CTDSP1 (0.42) PDE4BPDE4DTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PDE4B 161/4885PDE4D 485/4885PTGDR2 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.